+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 13 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of KarXT compared to a placebo in treating psychosis linked to Alzheimers Disease. This Phase 3 outpatient study lasts 38 weeks and aims to prevent relapse of psychosis symptoms in affected adults aged 55 to 90. The trial also looks at how long participants stay on treatment without relapse or stopping for any reason, along with monitoring safety and tolerability. Participants are randomly assigned to receive either KarXT capsules in varying doses or placebo capsules. The treatment is administered three times a day during the study period. This double-blind trial ensures neither participants nor researchers know which treatment is given. The study is conducted at multiple centers and includes a placebo control to compare outcomes. Throughout the 38 weeks, participants will attend regular visits for assessments including cognitive tests like the Mini-Mental State Examination, evaluations of psychosis severity, caregiver-reported measures, and safety monitoring such as laboratory tests, vital signs, and adverse event tracking. Researchers will measure the time to relapse and treatment discontinuation, along with side effects and other health indicators. The study is sponsored by Karuna Therapeutics, a Bristol Myers Squibb company.

Age: 55Years - 90YearsAll GendersPhase 3
129 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of KarXT in adults aged 55 to 90 years with mild to severe Alzheimers Disease that includes moderate to severe psychosis symptoms. This Phase 3 study focuses on treating psychosis related to Alzheimers Disease using a randomized, double-blind, placebo-controlled design. Participants receive either KarXT or a placebo at specified doses on scheduled days. The study lasts up to 14 weeks, during which the impact of KarXT on hallucinations, delusions, and other neuropsychiatric symptoms is assessed. The research also monitors various safety measures and cognitive function throughout this period. During the study, participants undergo evaluations including neuropsychiatric inventories, clinical global impression scales, cognitive tests like the Mini-Mental State Examination and Alzheimers Disease Assessment Scale, as well as safety monitoring through laboratory tests, vital signs, ECGs, and assessments for adverse events. The primary outcome is the change in hallucinations and delusions score up to week 14, with ongoing safety and efficacy assessments throughout the treatment period.

Age: 55Years - 90YearsAll GendersPhase 3
296 locations
E

Actively Recruiting

Researchers are evaluating the efficacy of claseprubart DNTH103 compared to placebo in adults with chronic inflammatory demyelinating polyneuropathy CIDP. This Phase 3 study aims to assess whether claseprubart can improve outcomes in participants with typical or variant forms of CIDP, including motor or multifocal types. The study is sponsored by Dianthus Therapeutics and involves several treatment periods to carefully measure the drugs impact. The study consists of multiple parts Part A includes an open-label phase lasting up to 13 weeks where participants receive an intravenous loading dose of claseprubart followed by subcutaneous injections every two weeks. Part B is a randomized, double-blind period lasting up to 52 weeks where participants who responded in Part A receive either claseprubart or placebo as subcutaneous injections every two weeks. Eligible participants may then join an optional open-label extension lasting up to 104 weeks receiving claseprubart injections every two weeks. A safety follow-up period of 40 weeks follows to monitor long-term effects. Participants will undergo various assessments throughout the study, including evaluations of neurological function and disease activity using scales such as the Adjusted Inflammatory Neuropathy Cause and Treatment INCAT score, Inflammatory Rasch-built Overall Disability Scale I-RODS, grip strength measurements, and other strength and disability scales. Researchers will also monitor for adverse events, measure serum drug concentrations, and evaluate immune responses. The total participation time may extend over several years, with regular visits for treatment administration, monitoring, and safety follow-up.

Age: 18Years - 75YearsAll GendersPhase 3
201 locations
S

Actively Recruiting

Healthy Volunteer

This research aims to evaluate a new advanced wireless skin sensor system designed to monitor vital signs in healthy newborn infants of at least 35 weeks gestational age. The study focuses on assessing the feasibility, safety, and accuracy of this wireless system compared to the standard wired monitoring during the first two hours after birth, especially during unsupervised parental care in the obstetrical center. The goal is to improve early detection and prevention of Sudden Unexpected Postnatal Collapse SUPC, a rare but serious condition affecting newborns shortly after delivery. Participants will have both the wireless monitoring system and the standard wired system placed on their chest and limb. For vaginal births, the wireless system is placed first, followed by the wired system after 15-20 minutes for C-section births, the order of placement is randomized. Both monitoring systems remain in place for two hours to continuously record vital signs such as heart rate, respiratory rate, oxygen saturation, and skin temperature. During the study, newborns vital signs will be recorded and compared between the two systems for up to two hours immediately after delivery. Researchers will evaluate the feasibility by checking for gaps in data and user satisfaction, assess safety through skin and pain scores, and measure accuracy using statistical comparisons. The study also includes monitoring the time between sensor placement and data display. Participation lasts only the initial two-hour period after birth, with monitoring done under real-world conditions in the obstetrical center.

Age: 35Weeks - 42WeeksAll GendersPhase Not Applicable
5 locations
O

Actively Recruiting

Researchers are observing women undergoing endoscopic nipple-sparing mastectomy NSM with immediate breast reconstruction, a procedure used for breast cancer treatment or prophylactic mastectomy due to hereditary risk. This study aims to collect real-world data on the feasibility, safety, sensory recovery, quality of life, and long-term oncological outcomes of this minimally invasive surgery. It focuses on adult women eligible for implant-based reconstruction, assessing surgical and cancer-related results over several years. Participants undergo endoscopic NSM through a lateral inframammary incision combining open and endoscopic techniques, with intraoperative assessments and axillary staging performed when needed. Immediate prepectoral implant-based reconstruction follows the surgery. No experimental treatments or changes to usual care are applied, as this is an observational study capturing outcomes from routine clinical practice. Throughout the study, data on clinical, surgical, pathological, and follow-up evaluations are collected, including patient questionnaires on satisfaction and quality of life. Assessments occur before surgery, during, and at multiple time points up to five years after surgery. Researchers monitor surgical complications, nipple-areola complex sensation recovery, cancer recurrence, survival, and aesthetic results. Each participant is followed for five years to evaluate long-term safety and effectiveness.

Age: 18Years - 75YearsFEMALE
1 location
C

Actively Recruiting

Researchers are conducting the PANThEON trial, a randomized, open-label, multicenter phase III study, to compare two chemotherapy approaches in patients with advanced pancreatic adenocarcinoma that cannot be surgically removed or has spread. The study aims to evaluate overall survival by comparing continuing modified FOLFIRINOX versus switching to gemcitabine plus nab-paclitaxel after initial induction chemotherapy. Eligible patients have stable or responding disease after about 3 months of initial mFOLFIRINOX treatment. During the study, all participants first receive induction chemotherapy with mFOLFIRINOX for up to 14 weeks, consisting of about six cycles every two weeks. Patients who show no disease progression are then randomly assigned to either continue mFOLFIRINOX Arm A or switch to gemcitabine plus nab-paclitaxel Arm B. Arm A treatments include oxaliplatin, irinotecan, leucovorin, and 5-fluorouracil given every two weeks until progression or unacceptable side effects. Arm B treatments involve gemcitabine and nab-paclitaxel administered on days 1, 8, and 15 of each 28-day cycle until progression or toxicity. Participants will have tumor imaging before and after induction chemotherapy to assess response. Throughout the trial, researchers will monitor overall survival up to 48 months, along with other outcomes like progression-free survival, treatment failure time, response rates, quality of life, and treatment toxicity. Safety and disease status will be regularly assessed, and participants may continue treatment or withdraw as needed. The trial is expected to last until 2030, with ongoing follow-up for health status and outcomes.

Age: 18Years +All GendersPhase 3
28 locations
E

Actively Recruiting

This research aims to evaluate the effectiveness of hypnotic communication in reducing emotional distress such as stress, anxiety, depression, anger, and the need for help in adult patients undergoing elective coronary angiography. Emotional stress from medical procedures, especially surgical ones, can negatively affect clinical outcomes and recovery. The study will be conducted as a randomized controlled trial involving 306 adults at the Cardiology Unit of Ospedale degli Infermi in Biella, Italy. Participants will be randomly assigned to one of two groups an experimental group receiving hypnotic communication alongside standard care, and a control group receiving standard care only. Hypnotic communication, delivered by trained nurses, follows a five-phase process pre-induction, induction, core, de-induction, and closure and begins at the patients bedside before the procedure, continuing through its completion. This technique uses empathetic, suggestion-based language without formal hypnosis to help manage emotional distress. During the study, participants emotional states will be assessed before preparation for the procedure and one hour after completion using the Emotion Thermometer Tool. Pain levels will also be measured 15 and 60 minutes after the procedure, and patient satisfaction with the communication technique will be recorded in the experimental group. Data will be collected at enrollment, before intervention, during, and after the procedure, with ethical approval and informed consent obtained. The study aims to support integrating hypnotic communication into routine care to improve patient well-being during invasive procedures.

Age: 18Years +All GendersPhase Not Applicable
1 location
P

Actively Recruiting

Researchers are evaluating the combination of brenetafusp IMC-F106C plus nivolumab compared to standard nivolumab regimens in people with previously untreated advanced melanoma who are HLA-A*0201-positive. This phase 3, randomized, controlled study aims to understand how these treatments perform in this specific group. The study focuses on improving progression-free survival and overall outcomes for participants with advanced melanoma. Participants are assigned to one of three groups one group receives a low dose of brenetafusp once weekly for 13 weeks, then every two weeks until Week 51, and every four weeks thereafter, along with nivolumab every four weeks another group receives a high dose of brenetafusp on the same schedule plus nivolumab the third group receives nivolumab alone or nivolumab combined with relatlimab every four weeks. The study includes a dose recommendation phase with changes made in November 2025 based on safety and efficacy data. During the study, participants undergo assessments including tumor measurements per RECIST 1.1, BRAF V600 mutation status evaluation, and performance status scoring. Researchers will monitor progression-free survival up to approximately 45 months, overall survival up to 57 months, and record adverse events, immune responses, and quality of life. The study involves regular dosing and long-term follow-up to evaluate treatment effects and safety.

Age: 18Years +All GendersPhase 3
211 locations
P

Actively Recruiting

Researchers are evaluating whether letrozole is more effective than standard chemotherapy for treating patients with hormone receptor positive low-grade serous epithelial ovarian carcinoma LGSCO. This phase III, open-label, randomized trial aims to see if letrozole can extend progression-free survival compared to carboplatin and paclitaxel chemotherapy. The study also explores tumor response, quality of life, pain, overall survival, safety, and genetic markers related to the disease. Participants will be randomly assigned to one of two groups one group takes letrozole tablets daily by mouth for up to 60 months or until disease progression, while the other group receives carboplatin and paclitaxel intravenously on day 1 every 21 days for 6 to 8 cycles. The treatments are compared directly to assess their effects on cancer control and patient well-being. During the study, participants will have regular assessments including tumor response evaluations, quality of life questionnaires, pain inventory, and safety monitoring according to standard criteria. Genetic profiling and circulating tumor DNA will be analyzed to understand disease characteristics. Progression-free survival will be tracked for up to 84 months, with ongoing monitoring of overall survival and adverse events. Participants will be followed closely to observe treatment effects and side effects throughout the trial period.

Age: 18Years +FEMALEPhase 3
19 locations
S

Actively Recruiting

Researchers are studying the levels of Visfatin, a substance found in maternal milk, to understand its relationship with newborn conditions, especially newborn weight loss. The study focuses on measuring Visfatin concentrations in mothers during the postpartum period to explore its potential as a biomarker for predicting newborn health outcomes. This observational study involves collecting maternal milk samples at three specific times after birth 48 hours, 7 days, and 30 days. Additionally, Visfatin levels in maternal plasma or serum will be measured 1 to 2 days after delivery. The study also plans to analyze correlations between Visfatin levels and biological or clinical features of both mothers and newborns. Participants will provide milk and blood samples at the specified time points. Researchers will use an ELISA kit to analyze Visfatin levels across these samples. The study will track how these levels change over time and relate to newborn health and weight. This information aims to improve understanding of newborn weight changes and maternal factors. The study will continue to monitor Visfatin values up to 6 months after birth.

All AgesAll Genders
1 location

1-10 of 13

1